Gene Solutions is proud to announce our participation at the European Society for Medical Oncology (ESMO) Asia Congress 2024, taking place at the Suntec Singapore Convention & Exhibition Centre, Singapore.
“We are thrilled to present our latest research at this year’s Congress, spanning diverse areas of precision oncology, including early cancer detection, minimal residual disease (MRD) detection, relapse risk and treatment assessment, comprehensive genomic profiling (CGP), and latest findings in fusion-derived neoantigens for effective cancer vaccines design. This aligns with our mission to advance personalized oncology in Asia,” said Dr. Duy Sinh Nguyen, MD, PhD, Medical Head of Oncology at Gene Solutions.
Key Highlights from Gene Solutions’ Contributions
Oral Presentation:
Title: Homologous recombination deficiency testing in Vietnamese patients with ovarian cancer | 379MO | Nam H. Tran
- Session Name: Mini Oral session: Gynaecological cancers (ID 82)
- Session Date & Time: Sun, 08.12.2024 | 14:15 – 15:30
- Location: Hall 407, Suntec Singapore
Poster Presentation:
- Location: Exhibition area, Suntec Singapore
- Date & Time: Sat, 07.12.2024 | 17:50 – 18:45
| No. | Poster Title | Speaker | Presentation Number |
| 1 | Real-world experience with a multi-cancer early detection test in Southeast Asia | Merit Travel Grants | Dang L. Nguyen | 733P |
| 2 | Multimodal analysis of circulating tumor DNA (ctDNA) combining genetic and epigenetic alterations enhances assay sensitivity for multi-cancer early detection (MCED) | Merit Travel Grants | Hanh T. Nguyen | 523P |
| 3 | Differentiation between malignant and benign gastric lesions by multimodal plasma cell-free DNA analysis | Ho D. Vo | 170P |
| 4 | A blood ctDNA multimodal-based assay for early detection of aggressive cancer types lacking standard screening tests | Chi V. Nguyen | 524P |
| 5 | Tumor-naïve approach for circulating tumor DNA analysis in multiple types of cancer | Nguyen T. Tu | 497P |
| 6 | Real-world utilization and performance of circulating tumor DNA monitoring to predict cancer recurrence early in Southeast Asia | Van-Anh H. Nguyen | 509P |
| 7 | Circulating tumor DNA dynamics to predict response to tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer: An interim report | Giang H. Vu | 517P |
| 8 | Fusion-derived neoantigens: Broadening the horizons of personalized cancer immunotherapy | Tran B. Nguyen | 486P |
| 9 | Tumor comprehensive genomic profiling: clinical implications and utilization in VietNam | Phuc Nguyen | 500P |
About Gene Solutions:
Gene Solutions is a pioneering and prominent genetic testing company in Asia, dedicated to developing and providing access to next-generation genetic testing. The company supports:
- Reproductive Health: Offering unique Non-invasive Prenatal Testing (NIPT) that integrates screening for Recessive and Dominant Single-Gene Disorders.
- Clinical Oncology: Including Multi-cancer Early Detection (MCED), Comprehensive Genomic Profiling (CGP) for precision therapy selection, and Minimal Residual Disease (MRD) tracking using circulating tumor DNA (ctDNA) technology.
Gene Solutions envisions empowering healthcare in the region through advanced genomics and multi-dimensional artificial intelligence. With over 1.5 million tests provided to patients, the company demonstrates its commitment to accessible genetic testing services
